Answers are grounded in this paper and cite their sources.
Systematic review shows antagonist stretching has minimal impact on agonist performance and range of motion.
Background Stretching is widely used to increase the range of motion (ROM) of a joint and has been shown to impact both stretched and non-stretched limbs. Objective Given conflicting findings regarding the acute effects of antagonist muscle stretching on agonist performance (e.g., strength, power) and ROM, this meta-analysis aims to clarify these issues and identify moderating factors. Methods Following PRISMA 2020 and ethical publishing guidance, the protocol was registered in PROSPERO (CRD420251014186). MEDLINE/PubMed, Web of Science, and Scopus were searched from inception to April 2025. Eligibility followed PICOS criteria: healthy participants; unloaded static, dynamic or proprioceptive neuromuscular facilitation (PNF) stretching of an antagonist; passive control; agonist performance or ROM outcomes; randomised or controlled pre–post trials. Risk of bias was assessed with the PEDro scale. Where > 2 studies were available, pooled effects were calculated with a robust-variance-estimation random-effects model (robumeta R package); otherwise, results were described qualitatively. Effect sizes (SMD) were interpreted as trivial (< 0.2), small (0.2–0.49), moderate (0.5–0.79) or large (≥ 0.8). Moderator, subgroup, and sensitivity analyses examined stretch duration and stretching technique. Certainty of evidence was graded with GRADE. Results Nine eligible trials involving 302 healthy participants met the criteria. Antagonist stretching produced a trivial, non-significant improvement in agonist performance (SMD = 0.22, 95% CI − 0.10–0.56, p = 0.14; low certainty). Moderator analyses showed no influence of stretch duration per bout (< 120 s vs ≥ 120 s) or stretching type (static, dynamic, PNF). Qualitative synthesis for ROM parameters suggested weak evidence for a small agonist ROM increase. Funnel-plot inspection revealed no clear publication-bias pattern; Egger’s test was not applied (< 10 studies). Findings are constrained by small sample sizes, moderate heterogeneity and predominantly fair-quality trials, yielding low overall certainty. Conclusion Current evidence indicates no clinically meaningful acute effect of antagonist stretching on agonist performance or ROM, irrespective of stretch duration or technique. Larger, high-quality trials are required to establish whether antagonist stretching offers practical benefits.
No takes yet. Share an insight, caveat, or question.
Konrad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: